Barclays reiterates Overweight on ConAgra stock, $21 target By Investing.com

ConAgra reported Q3 FY2026 EPS of $0.39, missing consensus by $0.01, while organic sales grew 2.4% (volume +0.5%, price/mix +1.9%). Management narrowed FY26 guidance, setting EPS at the low end of $1.70–$1.85 (consensus $1.72) and citing a $0.10 headwind from Ardent Mills; operating margin expected near the high end of ~11.0%–11.5%. The stock trades at $15.26, down 36% over 12 months and ~1% above its 52-week low, while free cash flow yield (~12%) and dividend yield (8.91%) underpin valuation arguments; Barclays reiterated Overweight with a $21 target, Stifel and TD Cowen reiterated Holds at $19 and $14 respectively.

Analysis

ConAgra’s headline weakness looks like a concentrated accounting/earnings-source problem rather than a broad demand fracture; that implies the market is penalizing the whole business for a specific JV earnings swing. The key second-order impact is on working-capital and supplier dynamics: if milling-related margins remain depressed, expect procurement to push more volume toward lower-cost co-manufacturers and private-label processors, compressing CPG category profitability for incumbents with heavy frozen/snack footprints.

Over the next 3–12 months the main catalysts will be (a) clarity on JV cash distributions and cost pass-through mechanics, and (b) quarterly free-cash-flow conversion versus consensus assumptions — both drive real optionality for buybacks or an activist. Tail risks are macro-driven: faster-than-expected deterioration in household food budgets or a commodity spike could flip the FCF story into a leverage story; conversely, sustained category price realization would convert perceived risk into upside quickly.

From a competitive standpoint, peers with cleaner supply chains and less JV exposure (think broad cereal/snack players and private-label specialists) could out-execute on margin turns, creating attractive pair-trade opportunities. Management’s capital-allocation choices are the lever to watch: redeploying extra cash into buybacks or marketing could accelerate re-rating, while reinvestment into lower-return innovation would mute upside and extend the time horizon for recovery.

Consensus is underweighting the speed at which a single JV swing can be repaired operationally and how that mismatch shows up in cash flow rather than revenue. If you buy the thesis that the core portfolio remains structurally resilient, the current repricing creates an asymmetrical payoff over 9–18 months as headline risk decays and cash conversion re-accelerates.

Key Decisions for Investors

• Long CAG equity (size 2–3% portfolio): enter on any short-term weakness; target +30% total return in 12 months, stop-loss at -20% from entry. Rationale: asymmetric upside if JV headwind proves transitory and FCF conversion remains resilient.
• Pair trade — Long CAG / Short GIS (equal $ exposure) for 6–12 months: expected to capture relative margin-recovery if CAG’s restructuring/clearing of JV noise outpaces peer operational improvements. Risk: sector-wide demand shock will hurt both; unwind if relative performance reverses by >150bps.
• Options calendar flip: buy 12-month CAG LEAP calls ~20% OTM and sell 3-month near-the-money calls against position, roll every quarter. Risk limited to net premium; reward captures re-rating while funded by near-term time decay.
• Event hedge: buy 3-month CAG puts sized to cover 25–30% of equity long exposure ahead of the next JV/cash-flow update. This caps downside from a surprise deterioration in JV distributions or rapid commodity moves.